MSD (headquartered in Kenilworth, New Jersey, USA) has made the decision to spin-off products from its Women’s Health, trusted Legacy Brands, and Biosimilars businesses to form a new, independent company. This new company, named “Organon”, will become an independent, publicly traded company in 2021 with its global and US headquarters to be based in Jersey City, New Jersey, USA. We expect that additional Organon sites will be in the general vicinity of current MSD locations.
For this exciting new opportunity, we are seeking candidates with an entrepreneurial and learning spirit who are interested in a career of purpose, personal growth and leadership. Working together, we will make a significant impact on the health and lives of people around the world.
For more information about Organon, please click here